Zobrazeno 1 - 10 of 32 pro vyhledávání: '"Yoshifumi, Hori"'
1
Akademický článek
Prognostic Impact of Histologic Subtype and Divergent Differentiation in Patients with Metastatic Urothelial Carcinoma Treated with Enfortumab Vedotin: A Multicenter Retrospective Study
Autor: Akinori Minato, Nobuki Furubayashi, Yujiro Nagata, Toshihisa Tomoda, Hiroyuki Masaoka, Yoohyun Song, Yoshifumi Hori, Keijiro Kiyoshima, Takahito Negishi, Kentaro Kuroiwa, Narihito Seki, Ikko Tomisaki, Kenichi Harada, Motonobu Nakamura, Naohiro Fujimoto
Publikováno v: Current Oncology, Vol 31, Iss 2, Pp 862-871 (2024)
Subtype of urothelial carcinoma (SUC), defined here as urothelial carcinoma with any histologic subtype or divergent differentiation, is a clinically aggressive disease. However, the efficacy of enfortumab vedotin (EV) against SUC remains unclear. He
Externí odkaz: https://doaj.org/article/090e7c2b79cf474b85e1f11873b1d392
Zobrazit plný text záznamu
2
Akademický článek
Endoscopic features of gastrointestinal stromal tumor in the small intestine
Autor: Yutaro Ihara, Takehiro Torisu, Tomohiko Moriyama, Junji Umeno, Atsushi Hirano, Yasuharu Okamoto, Yoshifumi Hori, Hidetaka Yamamoto, Takanari Kitazono, Motohiro Esaki
Publikováno v: Intestinal Research, Vol 17, Iss 3, Pp 398-403 (2019)
Background/Aims Gastrointestinal stromal tumor (GIST) is one of the most common types of submucosal tumors (SMTs). Because of GIST’s malignant potential, it is crucial to differentiate it from other SMTs. The present study aimed to identify charact
Externí odkaz: https://doaj.org/article/e601f47ee38a477ea8e81f0a903a96f0
Zobrazit plný text záznamu
3
Dissociated response among multiple metastatic lesions in the patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors
Autor: Takahito Negishi, Tohru Nakagawa, Naotaka Nishiyama, Hiroshi Kitamura, Eijiro Okajima, Nobuki Furubayashi, Yoshifumi Hori, Kentarou Kuroiwa, Yuhyon Son, Narihito Seki, Toshihisa Tomoda, Motonobu Nakamura
Publikováno v: Japanese Journal of Clinical Oncology. 52:1430-1435
Introduction Metastases from renal cell carcinoma develop in various organs. However, the breadth of discrepancy in response to immune checkpoint inhibitors across tumor sites within the same individual remains unclear. Patients and methods We review
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15b9f11fb4a7ab9c938472a0090f084a
https://doi.org/10.1093/jjco/hyac144
Zobrazit plný text záznamu
4
Optimal Timing of Switching from Platinum-based Chemotherapy to Pembrolizumab for Advanced Urothelial Carcinoma Based on Real-world Data: A Multi-institutional Retrospective Study
Autor: Nobuki, Furubayashi, Futoshi, Morokuma, Toshihisa, Tomoda, Yoshifumi, Hori, Takahito, Negishi, Akihiro, Miura, Hiroki, Komori, Kentaro, Kuroiwa, Motonobu, Nakamura
Publikováno v: Anticancer Research. 42:1571-1577
The optimal timing of switching from platinum-based chemotherapy to pembrolizumab in patients with advanced urothelial carcinoma (UC) remains unclear.Thirty-four patients who received pembrolizumab as second-line treatment after first-line platinum-b
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f0b507b1f1908827c6a1bf43e3163ef1
https://doi.org/10.21873/anticanres.15631
Zobrazit plný text záznamu
5
Lymphoid and myeloid proliferative disorders associated with inflammatory bowel disease: a clinicopathological study of 15 cases
Autor: Yoshifumi Hori, Hidetaka Yamamoto, Shinichiro Kawatoko, Yui Nozaki, Takehiro Torisu, Koji Kato, Yuhki Koga, Hiroaki Miyoshi, Koichi Ohshima, Yuki Tateishi, Shotaro Nakamura, Takanari Kitazono, Yoshinao Oda
Publikováno v: Human Pathology. 120:88-98
Lymphoproliferative disorder (LPD) can occur in patients with inflammatory bowel disease (IBD) such as ulcerative colitis (UC) and Crohn's disease (CD). On rare occasions, patients with IBD develop myeloid neoplasms; however, the frequency and clinic
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55bab4ffd0c9f3e69359f1ed90784e50
https://doi.org/10.1016/j.humpath.2021.12.010
Zobrazit plný text záznamu
6
The Association of Clinical Outcomes with Posttreatment Changes in the Relative Eosinophil Counts and Neutrophil-to-Eosinophil Ratio in Patients with Advanced Urothelial Carcinoma Treated with Pembrolizumab
Autor: Motonobu Nakamura, Naotaka Sakamoto, Narihito Seki, Nobuki Furubayashi, Toshihisa Tomoda, YooHyun Song, Yoshifumi Hori, Kentaro Kuroiwa, Shingo Tamura, Akinori Minato, Takahito Negishi, Naohiro Fujimoto
Publikováno v: Cancer Management and Research
Nobuki Furubayashi,1 Akinori Minato,2 Takahito Negishi,1 Naotaka Sakamoto,3 Yoohyun Song,4 Yoshifumi Hori,5 Toshihisa Tomoda,6 Shingo Tamura,7 Kentaro Kuroiwa,5 Narihito Seki,4 Naohiro Fujimoto,2 Motonobu Nakamura1 1Department of Urology, National Ho
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::500ce6b05fc6f03552cda80e7da5c04a
https://doi.org/10.2147/cmar.s333823
Zobrazit plný text záznamu
8
Site-specific Response to Nivolumab in Renal Cell Carcinoma
Autor: Eijiro Okajima, Motonobu Nakamura, Naotaka Nishiyama, Narihito Seki, Yoshifumi Hori, Nobuki Furubayashi, Tohru Nakagawa, Kentarou Kuroiwa, Toshihisa Tomoda, Takahito Negishi, Hiroshi Kitamura, Yuhyon Son
Publikováno v: Anticancer Research. 41:1539-1545
Background/aim Nivolumab monotherapy for advanced/metastatic renal cell carcinoma (RCC) shows a survival benefit. The purpose of this study was to evaluate tumor responses to nivolumab in various metastatic and primary sites in patients with RCC. Pat
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::39e42825f1cf6fedcc1ff03ac307d37f
https://doi.org/10.21873/anticanres.14913
Zobrazit plný text záznamu
9
Effectiveness and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and bone metastases in real-world practice: A multi-institutional study
Autor: Takashi Matsumoto, Yoshifumi Hori, Masaki Shiota, Leandro Blas, Motonobu Nakamura, Narihito Seki, Kentaro Kuroiwa, Akira Yokomizo, Futoshi Morokuma, Keijiro Kiyoshima, Masatoshi Eto
Publikováno v: International journal of urology : official journal of the Japanese Urological AssociationREFERENCES.
Radium-223 (Ra-223) dichloride is the bone-targeted radioligand therapy that prolongs overall survival (OS) in patients with bone-metastatic castration-resistant prostate cancer (CRPC). We aimed to evaluate the safety and effectiveness of this treatm
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::94f4ada2462fd44163bdf1a523875569
https://pubmed.ncbi.nlm.nih.gov/36305673
Zobrazit plný text záznamu
10
Treating Japanese Patients With Pembrolizumab for Platinum-Refractory Advanced Urothelial Carcinoma in Real-World Clinical Practice
Autor: Masatoshi Kumagai, Nobuki Furubayashi, Toshihisa Tomoda, Yoshifumi Hori, Noriaki Tokuda, Motonobu Nakamura, Futoshi Morokuma, Tomohiro Inoue, Takahito Negishi, Kentaro Kuroiwa
Publikováno v: Journal of Clinical Medicine Research
Background: Since December 2017, pembrolizumab has been approved in Japan as a second-line treatment for radical unresectable urothelial carcinoma (UC) that has become exacerbated after chemotherapy by the international randomized phase 3 trial, KEYN
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5fa406f68a7b293a2b893a52ec40d2a1
https://doi.org/10.14740/jocmr4162
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje